This is a routine CFO transition with a qualified external hire. No immediate trading signal. Monitor upcoming earnings calls for any strategic commentary under new CFO.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $82.63entry
- T+1 · 7mo ago +0.38%α −1.01% · $82.94
- T+5 · 6mo ago −3.85%α −5.83% · $79.45
- T+20 · 6mo ago +6.09%α +1.14% · $87.66
- T+60 · 4mo ago +5.20%α +2.72% · $86.92
Price Chart
How similar events traded
Executive Summary
Edwards Lifesciences appoints Theodora Mistras as CFO, effective May 29, 2026, succeeding Scott Ullem in a planned transition. Mistras brings experience from Viatris and healthcare investment banking. The filing is a routine leadership change with no material financial impact.
Key Facts
- Theodora Mistras appointed Corporate Vice President and CFO, effective May 29, 2026.
- Mistras previously served as CFO of Viatris (NASDAQ: VTRS) and held senior roles at Citigroup and Goldman Sachs.
- Base salary of $925,000, sign-on bonus of $2,013,000, initial RSU grant of $8,000,000, and annual equity grant of $4,500,000 for fiscal 2026.
- Outgoing CFO Scott Ullem announced his planned transition in October 2025; no unexpected departure.
Financial Impact
Compensation package includes base salary $925k, sign-on bonus $2.013M, RSUs $8M, and annual equity $4.5M. No impact on company financials or guidance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001099800-26-000023 |
| Document: cfoofferletter.htm | 0001099800-26-000023 |
| Document: a8-kxexpressreleasexcfo.htm | 0001099800-26-000023 |
| Document: 0001099800-26-000023-index-headers.html | 0001099800-26-000023 |
| Document: 0001099800-26-000023-index.html | 0001099800-26-000023 |
| Document: 0001099800-26-000023.txt | 0001099800-26-000023 |
Track record
27 reports on EW
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +4.94% at T+5 after the Nov 4, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $100.82 to $105.80 Now $107.11 +6.24% ▲ +4.94% +1.65% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $94.44 to $100.82 Now $107.11 +13.42% ▲ +6.76% +11.48% vs SPY
- Aug 31, 202611w ago Insider Cluster Neutral 2/10 Entry $90.74 to $86.18 Now $107.11 +18.04% ▼ −5.03% −5.11% vs SPY
- Aug 28, 202611w ago Insider Cluster Neutral 2/10 Entry $90.75 to $86.72 Now $107.11 +18.03% ▼ −4.44% −4.30% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers